[ad_1]
JOHANNESBURG, July 24 (Reuters) – South Africa has a history of high blood pressure and high blood pressure. .
This follows similar moves taken in Europe after the European Medicines Agency (EMA) raised the potential of cancer by China's Zhejiang Huahai Pharmaceutical.
"This review was triggered because of the detection of an impurity, N-nitrosodimethylamine (NDMA) in the valsartan active substance which the company supplies," the South African Health Products Regulatory Authority said in a statement.
The health authority said not all valsartan-contaning medicines are affected, but only Dynaval Co tablets.
Valsartan-containing medicinal products are commonly used to treat high blood pressure in patients with high blood pressure, and those who have had heart failure or a recent heart attack.
Zhejiang Huahai has already had some of its valsartan, which said it was worth $ 50 million in 2017 and added that it was a precautionary measure.
Reporting by Nqobile Dludla
Editing by James Macharia and Emelia Sithole-Matarise
Source link
